Patient characteristics
| Characteristics . | Total . | R/R . | Newly diagnosed . |
|---|---|---|---|
| N = 19 | n = 8 | n = 11 | |
| Age, median (range), y | 64 (23-82) | 45.5 (23-82) | 68 (61-78) |
| Male/female | 15/4 | 6/2 | 9/2 |
| Immunophenotype | |||
| B-cell (CD20+) | 11 (7) | 3 (0) | 8 (7) |
| T-cell (ETP) | 8 (4) | 5 (3) | 3 (1) |
| Cytogenetics | |||
| Normal | 7 | 4 | 3 |
| Complex | 5 | 4 | 1 |
| Hypodiploid/near-triploid | 6 | 0 | 6 |
| Hyperdiploid | 1 | 0 | 1 |
| TP53 mutation | 12 | 6 | 6 |
| Prior therapy | |||
| Median prior lines (range) | — | 2 (1-5) | — |
| Prior HSCT | — | 5 | — |
| Therapy related (multiple myeloma) | 3 | 0 | 3 |
| Characteristics . | Total . | R/R . | Newly diagnosed . |
|---|---|---|---|
| N = 19 | n = 8 | n = 11 | |
| Age, median (range), y | 64 (23-82) | 45.5 (23-82) | 68 (61-78) |
| Male/female | 15/4 | 6/2 | 9/2 |
| Immunophenotype | |||
| B-cell (CD20+) | 11 (7) | 3 (0) | 8 (7) |
| T-cell (ETP) | 8 (4) | 5 (3) | 3 (1) |
| Cytogenetics | |||
| Normal | 7 | 4 | 3 |
| Complex | 5 | 4 | 1 |
| Hypodiploid/near-triploid | 6 | 0 | 6 |
| Hyperdiploid | 1 | 0 | 1 |
| TP53 mutation | 12 | 6 | 6 |
| Prior therapy | |||
| Median prior lines (range) | — | 2 (1-5) | — |
| Prior HSCT | — | 5 | — |
| Therapy related (multiple myeloma) | 3 | 0 | 3 |